journal article·2019-04

Renal perfusion assessment using magnetic nanoparticles with 7T dynamic susceptibility contrast MRI in rats

Yen-Ling Lin, Yu-Chun Lin, Li-Jen Wang, Sin-Ting Ngo, Yunn-Hwa Ma

Publisher page

Abstract

Abstract Magnetic nanoparticles (MNPs) can be used as magnetic resonance imaging (MRI) contrast agent with dynamic susceptibility contrast (DSC) MRI, which is an important in vivo method to assess organ perfusion with multiple clinical applications. Since variations in particle size and PEGylation of MNPs may potentially influence particle-tissue interactions in the microcirculation, we evaluate their effects on rat kidneys with DSC MRI. Anesthetized Sprague Dawley rats were cannulated for intravenous injection of dextran-coated MNPs (50 nm and 250 nm; 5 mg/kg) with or without PEGylation during acquirement of DSC MRI images. The results demonstrate that both particle size and PEGylation may alter perfusion parameters. Relative mean transit time (rMTT) of 50 nm particles is 1.8 fold of that of 250 nm particles with or without PEGylation. In MNPs of 50 nm, PEGylation is associated with 38% and 25% shorter time-to-peak (TTP) and time from onset to 50% drop from peak (T50), respectively; however, PEGylation exerts no effect on these parameters of 250 nm particles. Nevertheless, particle size or PEGylation exert no influence on the prediction of relative blood flow or relative blood volume of the kidney. In conclusion, DSC MRI is a feasible method to evaluate renal perfusion and properties of MNPs in circulation.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: MRI in cancer diagnosis · Advanced MRI Techniques and Applications · Lanthanide and Transition Metal Complexes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (53)

Show source-provided references
1. Magnetic iron oxide nanoparticles: synthesis, stabilization, vectorization, physicochemical characterizations, and biological applications10.1021/cr068445e ↗
2. Applications of magnetic nanoparticles in biomedicine10.1088/0022-3727/36/13/201 ↗
3. Magnetic nanoparticles in cancer theranostics10.7150/thno.11544 ↗
4. Biologically targeted magnetic hyperthermia: potential and limitations10.3389/fphar.2018.00831 ↗
5. Iron oxide nanoparticles for targeted cancer imaging and diagnostics10.1016/j.nano.2011.08.017 ↗
6. Specific E-selectin targeting with a superparamagnetic MRI contrast agent10.1002/cmmi.87 ↗
7. VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor10.1016/j.nano.2014.12.011 ↗
8. PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer10.2217/nnm.14.122 ↗
9. A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
10. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coated with anti-epidermal growth factor receptor antibody10.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5 ↗
11. MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles10.1002/mrm.10406 ↗
12. Nanoparticle-based targeted drug delivery10.1016/j.yexmp.2008.12.004 ↗
13. Nanoparticles as drug delivery systems10.1016/S1734-1140(12)70901-5 ↗
14. Development of magnetic nanoparticles for cancer gene therapy: a comprehensive review10.1155/2013/646284 ↗
15. Magnetic nanoparticles and targeted drug delivering10.1016/j.phrs.2010.01.014 ↗
16. An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma10.2147/IJN.S32900 ↗
17. Applications of ultrasmall superparamagnetic iron oxide contrast agents in the MR study of animal models10.1002/nbm.923 ↗
18. MR contrast due to intravascular magnetic susceptibility perturbations10.1002/mrm.1910340412 ↗
19. Intravascular susceptibility contrast mechanisms in tissues10.1002/mrm.1910310103 ↗
20. The design and utility of polymer-stabilized iron-oxide nanoparticles for nanomedicine applications10.1038/asiamat.2010.6 ↗
21. PEGylation of surfacted magnetite core–shell nanoparticles for biomedical application10.1016/j.colsurfa.2014.01.043 ↗
22. Nanoparticle PEGylation for imaging and therapy10.2217/nnm.11.19 ↗
23. Polyethylene glycol modified, cross-linked starch-coated iron oxide nanoparticles for enhanced magnetic tumor targeting10.1016/j.biomaterials.2010.11.040 ↗
24. A versatile and tunable coating strategy allows control of nanocrystal delivery to cell types in the liver10.1021/bc1003179 ↗
25. MR perfusion imaging of the brain: techniques and applications10.2214/ajr.175.1.1750207 ↗
26. Renal artery stenosis: functional assessment with dynamic MR perfusion measurements–feasibility study10.1148/radiol.2382041553 ↗
27. Diffusion and perfusion of the kidney10.1016/j.ejrad.2010.05.033 ↗
28. Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma10.1158/1078-0432.CCR-06-1921 ↗
29. Perfusion imaging in renal diseases10.1016/j.diii.2013.08.018 ↗
30. Wang · 2015
31. Quantification of renal perfusion abnormalities using an intravascular contrast agent (part 2): results in animals and humans with renal artery stenosis10.1002/mrm.10383 ↗
32. USPIO-enhanced dynamic MRI: evaluation of normal and transplanted rat kidneys10.1002/mrm.1312 ↗
33. Subclinical acute kidney injury (AKI) due to iodine-based contrast media10.1007/s00330-012-2607-y ↗
34. Nephrogenic systemic fibrosis: risk factors and incidence estimation10.1148/radiol.2431062144 ↗
35. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles10.1039/C5CS00541H ↗
36. CBF and CBV measurements by USPIO bolus tracking: reproducibility and comparison with Gd-based values10.1002/(SICI)1522-2586(199902)9:2<342::AID-JMRI29>3.0.CO;2-B ↗
37. Emerging applications for ferumoxytol as a contrast agent in MRI10.1002/jmri.24691 ↗
38. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?10.1038/ki.2008.496 ↗
39. Ferumoxytol-enhanced magnetic resonance imaging in late-stage CKD10.1053/j.ajkd.2015.12.017 ↗
40. Evaluation of a new ultrasmall superparamagnetic iron oxide contrast agent Clariscan, (NC100150) for MRI of renal perfusion: experimental study in an animal model10.1002/jmri.10149 ↗
41. Quantification of renal perfusion using an intravascular contrast agent (part 1): results in a canine model10.1002/mrm.10380 ↗
42. R Core Team · 2016
43. Quantification of renal perfusion and function on a voxel-by-voxel basis: a feasibility study10.1002/mrm.20608 ↗
44. On the theoretical basis of perfusion measurements by dynamic susceptibility contrast MRI10.1002/mrm.1307 ↗
45. Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques10.3348/kjr.2014.15.5.554 ↗
46. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: mathematical approach and statistical analysis10.1002/mrm.1910360510 ↗
47. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: experimental comparison and preliminary results10.1002/mrm.1910360511 ↗
48. On the theory of the indicator-dilution method for measurement of blood flow and volume10.1152/jappl.1954.6.12.731 ↗
49. Measuring signal-to-noise ratios in MR imaging10.1148/radiology.173.1.2781018 ↗
50. A comparison of two methods for measuring the signal to noise ratio on MR images10.1088/0031-9155/44/12/403 ↗
51. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane10.1073/pnas.1200718109 ↗
52. Long-circulating iron oxides for MR imaging10.1016/0169-409X(95)00033-4 ↗
53. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes10.1016/j.jacc.2010.09.023 ↗